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Abstract: Leucinostatin A is one of the most potent antipro-
tozoal compounds ever described, but little was known on
structure–activity relationships (SAR). We used Trypanosoma
brucei as a protozoal model organism to test synthetically
modified derivatives, resulting in simplified but equally active
compounds 2 (ZHAWOC6025) and 4 (ZHAWOC6027),
which were subsequently modified in all regions of the
molecule to gain an in-depth SAR understanding. The
antiprotozoal SAR matched SAR in phospholipid liposomes,
where membrane integrity, leaking, and dynamics were
studied. The mode of action is discussed based on a struc-
ture–activity analysis of derivatives in efficacy, ultrastructural
studies in T. brucei, and artificial membrane models, mimick-
ing membrane stability and membrane potential. The main site
of antiprotozoal action of natural and synthetic leucinostatins
lies in the destabilization of the inner mitochondrial mem-
brane, as demonstrated by ultrastructural analysis, electron
microscopy and mitochondrial staining. Long-time sublethal
exposure of T. brucei (200 passages) and siRNA screening of
12’000 mutants showed no signs of resistance development to
the synthetic derivatives.
Introduction
Leucinostatins, antimicrobial peptides (AMPs) from the
biocontrol agent Purpureocillium lilacinum, are among the
most potent antiprotozoal agents ever discovered, with some
of them being among the most toxic oral mycotoxins known.
The term leucinostatin was coined in 1973 for a substance
isolated from a fungal fermentation broth. The name
leucinostatin was given due to the apparent presence of
several leucines, even though the definite structure was yet
unsolved.[1] In 1982 Mori et al. demonstrated that the initial
leucinostatin[1] was in fact a mixture of several similar
compounds and established the structure of the main
component leucinostatin A (1a) by mass spectrometric,
NMR, IR and degradative methods. The compound com-
prised nine a-amino acid residues, including cis-4-methyl-L-
proline, (2S)-amino-(6R)-hydroxy-(4S)-methyl-8-oxodecano-
ic acid (AHMOD), hydroxyleucine and 2-aminoisobutyric
amino acids (Aib), as well as fatty acyl moieties consisting of
seven carbon atoms at the N-terminus (Figure 1).[2] A year
later the same group published the structure of the demethy-
lated derivative leucinostatin B (1b).[3] In 1989 the crystal
structure of leucinostatin A was established and the a-helical
conformation confirmed.[4] With the emergence of tandem
mass-spectrometry, more than 20 minor leucinostatin A
derivatives with demethylation/oxidation at the N-terminal
dimethylamine, the methyl proline, and deletions or changes
in the oxidation of the AHMOD sidechain were detected and
named alphabetically.[5, 6] The total synthesis of leucinostatin
A (1a) was achieved by Abe et al. (2017), which pointed out
the configuration of the previous assumed chirality of the
AHMOD side chain hydroxyl group was wrong.[7] The
biosynthetic route was studied, and the core biosynthetic
genes, which are specific to P. lilacinum and Tolypocladium
inflatum ophioglossoides, were identified.[8]
Since the seminal work by Arai et al. , whose new anti-
biotic leucinostatin consisted of a mixture of leucinostatins A
and B,[1] it has become evident that leucinostatins a) inhibit
the proliferation of many different organisms and b) are very
toxic. The reported effects against pathogens include 21 fungi
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Prof. Dr. R. Riedl
Institute of Chemistry and Biotechnology, Center for Organic and
Medicinal Chemistry, Zurich University of Applied Sciences (ZHAW)
Einsiedlerstrasse 31, 8820 W-denswil (Switzerland)
E-mail: rainer.riedl@zhaw.ch
Dr. M. Kaiser, Dr. R. S. Schmidt, A. Ritschl, Prof. Dr. P. M-ser
Swiss Tropical and Public Health Institute
Socinstrasse 57, 4051 Basel (Switzerland),
and
University of Basel
Petersplatz 1, 4001 Basel (Switzerland)
Dr. L. Wang, J. Jelk, Prof. Dr. P. Bftikofer
Institute of Biochemistry and Molecular Medicine, University of Bern
Bfhlstrasse 28, 3012 Bern (Switzerland)
Prof. Dr. A. Hemphill
Institute of Parasitology, Vetsuisse Faculty, University of Bern
L-nggass-Strasse 122, 3012 Bern (Switzerland)
Dr. M. Adams
Bacoba AG
Elisabethenstrasse 15, 4051 Basel (Switzerland)
E-mail: adams@bacoba.ch
Supporting information and the ORCID identification number(s) for
the author(s) of this article can be found under:
https://doi.org/10.1002/anie.202102153.
T 2021 The Authors. Angewandte Chemie International Edition
published by Wiley-VCH GmbH. This is an open access article under
the terms of the Creative Commons Attribution Non-Commercial
NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-
commercial and no modifications or adaptations are made.
Angewandte
ChemieResearch Articles
How to cite: Angew. Chem. Int. Ed. 2021, 60, 15613–15621
International Edition: doi.org/10.1002/anie.202102153
German Edition: doi.org/10.1002/ange.202102153
15613Angew. Chem. Int. Ed. 2021, 60, 15613 – 15621 T 2021 The Authors. Angewandte Chemie International Edition published by Wiley-VCH GmbH
(Minimal Inhibitory Concentrations=MICs: 10–25 mM) and
gram-positive bacteria (2.5–100 mM). In addition, leucinosta-
tin was highly toxic in mice with intraperitoneal (ip) LD50 of
1.6 mgkg@1. Mikami et al. showed that the ip LD50s of purified
leucinostatins A (1a) and B (1b) were both 1.8 mgkg@1, and
the oral LD50s were 5.4 mgkg
@1 and 6.3 mgkg@1, respectively,
and stated that they “belong to a category of the most toxic
mycotoxins, such as T-2 toxin, fusarenone-X and aflatoxins”.[9]
Others have confirmed the acute toxicity, including Ricci
et al. , whose leucinostatin A (1a) had an ip LD50 in mice of
1.1 mgkg@1.[10]
This toxicity has prevented the therapeutic use of
leucinostatins. Although leucinostatins were first reported
as antibiotics,[1] achieving the necessary systemic concentra-
tions (MICs) to eliminate bacterial or fungal pathogens in
mammals might exceed their lethal dose.
One group of pathogens, however, the pathogenic proto-
zoa, proved to be hypersusceptible to leucinostatins. Otoguro
et al. first showed that leucinostatin A (1a) inhibited Plasmo-
dium falciparum (the causative agent of malaria tropica) at an
IC50 of 0.4–0.9 nM, and Trypanosoma brucei (the causative
agent of Human African Trypanosomiasis (HAT)) at an IC50
of 2.8 nM.[11] In the T. brucei acute HAT mouse model,
leucinostatin B (1b) showed curative effects at a dose of 4X
0.3 mgkg@1 ip and 4X 1.0 mgkg@1 ip, whereas leucinostatin A
(1a) (which was not tested higher due to toxicity) did not at
4X 0.3 mgkg@1 ip.[12] In another HATacute mouse model, one
of 4 mice was cured with leucinostatin B at 4X 1.0 mgkg@1 ip
and the mean duration of survival was raised from 11.3 days
to 28 days, whilst at 4X 0.3 mgkg@1 ip no mice were cured but
the mean duration of survival was slightly increased com-
pared to untreated mice.[12]
The mode of action of leucinostatins has been linked to
their general destabilizing effect on biological membranes in
both artificial membrane systems and living cells,[13–16] which
may explain the non-specific toxicity towards bacteria, fungi,
and mammalian cells in the mM range. Leucinostatins are
classic peptaibiotics that contain a high proportion of
unnatural Aibs, which tend to form 310-helical structures,
[17]
and hydrophobic amino acid residues.[18] Leucinostatin be-
longs to the subclass of AHMOD containing aminolipopep-
tides.[18]
Little is known about the structural requirement for
antiprotozoal activity of leucinostatins and their mode of
action. Vertuani et al. obtained eight leucinostatin A homo-
logues by reduction, dehydration and acetylation of the 4-
methylhex-2-enoic acid, AHMOD and hydroxy-L-leucine
residues, and screened for antibacterial activity.[19] Those
subtle modifications did not result in a significant change of
the antibacterial activity and had no effect on the secondary
structure. Abe et al. performed an alanine scan and reported
a concise structure activity relationship (SAR) on tumor cells
and tumor-stroma interaction.[20] They reported that the acyl
group on the N-terminus is essential for biological activity.
Replacement of the unsaturated acyl chain with acetyl
resulted in a 1000-fold decrease of the affinity. In addition,
alanine scanning revealed that only the replacement of Aib-2
was tolerated, whereas replacement of amino acids Aib-3,
Leu-5 and AHMOD-8 reduced the activity by an order of
Figure 1. Structural optimization of the natural product leucinostatin A
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magnitude. Momose et al. showed that leucinostatin Y, having
a carboxylic acid instead of a terminal amine, was far less
active against bacteria, fungi, and cancer cells than leucinos-
tatin A (1a).[21] However, comprehensive structure–activity
relationships (SAR) have not been reported, and pressing
issues remain unanswered. Here we present the first compre-
hensive structure–activity relationship of leucinostatin deriv-
atives, determine the structural imperatives for in vitro
antiprotozoal activity, and optimize the selectivity of the
molecules.
Results and Discussion
We envisioned to simplify the complex structure of
leucinostatin A (1a) while maintaining the potency on T. b.
rhodesiense. The synthetic strategy was based on microwave-
assisted solid-phase peptide synthesis (SPPS), followed by
a final solution-phase amide coupling of the 9-mer carboxylic
acid peptide with the terminal amine (Scheme S1). In the
course of the study, the presence of the antiprotozoal
pharmacophore was traceable by phenotypic in vitro assays,
and we determined which moieties were responsible for the
antiprotozoal activity. This led to a comprehensive under-
standing of the structure–activity relationship.
Replacing the hydroxyleucine at position 7 with a simple
and cheap leucine was tolerated and had no negative impact
on the biological activity. The Michael acceptor was replaced
by either 4-fluorobenzoic acid or an oxazole. The dimethyl
amine ethylenamide linker (6) on the C-terminus was
functionalized with a cyclobutyl amine, as the metabolic
stability was thought to be increased and it had little impact
on T. b. rhodesiense antiprotozoal potency. The side chain
does not need to be an AHMOD acid and can be replaced.
Ethyl cyclohexyl or n-octyl sidechain yielded the most potent
compounds, that is, 2, 4 and 6, with sub-nanomolar potencies
comparable to that of the natural product leucinostatin A
(Table 1). These modifications not only maintained the
activity against T. brucei but also increased the selectivity
index between 3- and 5-fold. The hydrophobicity of this side
chain is important as modifications, such as replacing it with
glutamic acid (7) or the shorter n-butyl (8) aliphatic chain,
reduced the in vitro potency, whereas the n-hexyl (10)
analogue still had comparable potency to 2. It seems that
modification of this amino acid has a much bigger influence
on parasites compared to the recently published work from
Abe et al. on cancer cell lines.[20] The peptide 5, consisting of
unnatural D-amino acids, showed similar activity against T. b.
rhodesiense as 2 with an IC50 of 1.5 nM, meaning both the left
and right hand helix are active, which indicates this compound
class does not engage with a protein target. Compound 3 N-
methylated at the leucine amide at position four of the
peptide backbone resulted in a 500-fold decrease in activity.
Studies on the dimethyl amine at the C-terminus revealed that
reducing the basicity of the amine by introduction of a s-
acceptor[22] with either a morpholine (14) or a difluoro ethyl
methyl amine (15) reduced the potency. The experimentally
determined pKa values of the dimethyl amines (4 and 13)
were 7.3, the morpholine (14) had a pKa of 5.2, and the
difluoro ethyl methyl amine (15) a pKa < 3.5. As these
compounds exhibited the same cytotoxicity (7 mM), it is clear
that the increase of basicity changes this compound class from
a rather cytotoxic (15, selectivity index (SI) 17) to a highly
selective compound (13, SI 1694).
Table 1: Activity of leucinostatin A and its derivatives on T. b. rhodesiense
and the cytotoxicity on L6 cells and the calculated selectivity index (SI).
The leucinostatin derivatives are compared to the reference drugs
melarsoprol, pentamidine and suramin.






























































































NA=not applicable; [a] n=2; [b] n=3; [c] n=4; [d] n=9, [e] n=8.
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Overall, a synthetic, more accessible lead compound was
obtained with equipotent activity on T. b. rhodesiense but
reduced cytotoxicity compared to the natural product. In
comparison to the currently available drugs, our synthetic
derivatives are superior in regard of their antitrypanosomal
potency (Table 1).
In order to gain further insights on the effects of the
modifications, analysis of the secondary structure by circular
dichroism (CD) spectrometry was performed of leucinostatin
A (1a), 2, 3, 4, 5, and 7. All of the leucinostatin derivatives
showed helical character, with the exception of the N-
methylated compound 3 (supporting information section 3.1),
clearly indicating the helix is an important feature for
antiprotozoal activity. This shows that methylation of the
leucine amide disables helix formation and hence results in
massive decrease of anti-parasitic activity.
The helical character of 4 was confirmed by NMR-NOE
experiments (Figure S1). Additionally, the kinetics of the
deuterium exchange of the backbone amide of 4 in CD3OD
showed that the backbone amide protons 2 to 4 persist with
a t1=2 > 1 hour, with 2 having the longest half-life time of
12.5 hours (Figure S2).
In summary, a helix-forming backbone, the basic terminal
amine, and the hydrophobic side chain are crucial for
biological activity. As linear peptides are known to be
susceptible for fast metabolism, microsomal stability was
measured. Both of our lead compounds 2 and 4 showed very
encouraging microsomal stability, in particular compound 4
(> 80% recovery after 40 minutes, supporting information
section 3.5).
Studies on the morphological and cellular effects of the
leucinostatin derivatives were done on T. b. brucei, which is
a subspecies of T. brucei and a causative agent of Nagana,
a widespread cattle disease in sub-Saharan Africa. It was
therefore necessary to establish the inhibitory effects of the
experimental compounds on T. b. brucei as well. The activities
of leucinostatin A (1a) (0.4 nM), 2 (6.4 nM), 4 (3.6 nM) and 7
(> 1000 nM) were comparable to the values obtained against
T. b. rhodesiense.
Confirmation of In Vivo Efficacy
Compounds 2 (ip 3 mgkg@1 twice a day (bid) for 4 days,
and orally (po) 30 mgkg@1 once a day (qd) for 4 days) and 4
(ip 3 mgkg@1 bid 2 days) were tested for in vivo efficacy using
the T. b. brucei (STIB795) acute NMRI mouse model. The
mice had no detectable parasitemia (< 104 parasitesmL@1)
after the treatment with 2 (for 4 days) and 4 (for 2 days). The
survival of mice was prolonged compared to the untreated
controls (Figure 2). Interestingly, 2 (po 30 mgkg@1 qd 4 days)
was active also when given orally.
Mode of Action
Earlier studies have shown that leucinostatin A (1a) can
act as a ionophore on isolated mitochondrial and chloroplast
preparations[13–15] and increase membrane permeability of
cells and artificial membranes by facilitating transport of
monovalent and divalent cations.[14] In addition, in model
liposomes, leucinostatin A underwent concentration-depen-
dent self-aggregation in the lipid bilayer, thereby affecting
lipid phase transition and membrane fluidity, and causing
membrane pore formation.[15] Similar observations have been
made for other cationic antimicrobial peptides, such as
melittin and magainin, which cause membrane damage by
inserting into lipid bilayers and forming transient or stable
pores.[23,24] Such pores may allow membrane lipids to freely
diffuse from one side of the bilayer to the other and small
hydrophilic molecules to cross the membrane. To study if the
leucinostatin derivatives synthesized in the present study are
capable of inducing transbilayer scrambling of phospholipids,
peptides were added to liposomes composed of egg phospha-
tidylcholine (PC), egg phosphatidylglycerol (PG) and trace
amounts of [3H]-labelled phosphatidylinositol ([3H]PI), with
the label at the inositol, and treated with PI-specific
phospholipase C (PI-PLC). In control liposomes, treatment
by PI-PLC should result in hydrolysis of approximately 50%
of [3H]PI, that is, the portion of [3H]PI present in the outer
leaflet of the bilayer (Figure 3a). In contrast, if leucinostatins
induce transbilayer movement of phospholipids, all [3H]PI
should be available to PI-PLC after addition of peptides to
liposomes (Figure 3a).[25] The extent of [3H]PI hydrolysis
increased from 50% in control liposomes to > 80% in
liposomes after addition of increasing amounts of peptides
1a, 2 or 4 (Figure 3b). These results are consistent with
peptide-induced translocation of [3H]PI from the inner to the
outer leaflet of liposomes. In contrast, no redistribution of
[3H]PI was observed after addition of the non-antiprotozoal
peptide 7 to liposomes (Figure 3b).
In addition, the formation of membrane pores was
assayed using liposomes containing trapped NBD-glucose.
In control liposomes, NBD-glucose remains in the lumen of
the liposomes and, thus, its fluorescence cannot be reduced by
membrane-impermeable dithionite present in the solution
(Figure 3c). In contrast, if the addition of peptides to
liposomes results in pore formation, entrapped NBD-glucose
can diffuse out of the liposomes, or alternatively dithionite
can enter the liposomes, and NBD fluorescence will be
Figure 2. Kaplan-Meier plot of the in vivo experiment on T. b. brucei
(STIB795) acute NMRI mouse model treated with vehicle, 2 (ip and
po) and 4 (ip). n=4.
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reduced (Figure 3c). Addition of compounds 1a, 2 and 4 to
NBD-glucose loaded liposomes led to complete loss of
fluorescence (Figure 3d). In contrast, no reduction was
observed after addition of peptide 7, indicating that peptides
1a, 2 and 4 induced pore formation in liposomes while
peptide 7 was inactive. The above findings, that is, complete
hydrolysis of [3H]PI by PI-PLC and reduction of NBD-
glucose by dithionite, could also result from peptide-induced
lysis of liposomes. However, examination by electron micros-
copy revealed that liposomes after peptide treatment were
indistinguishable from control liposomes (Figure S3), ruling
out that the peptides acted as detergents causing lysis of the
liposomes.
To analyse leucinostatin activity on live trypanosomes, T.
b. brucei bloodstream forms were treated with compound 2
for 24 h before parasites were incubated with the mitochon-
drial membrane potential-dependent dye MitoTracker and
examined by fluorescence microscopy. The typical mitochon-
drial staining of control trypanosomes was completely absent
in parasites treated with compound 2 (Figure 4a,b), indicating
that addition of compound 2 resulted in loss of mitochondrial
membrane potential. Similar results were obtained with
compounds 4 and 5 (40 nM, final concentration). In contrast,
no changes in MitoTracker staining was observed when T.
brucei bloodstream forms were treated with compounds 3 and
7. To corroborate these findings, we quantified the mitochon-
drial membrane potential in parasites before and after drug
treatment using the mitochondrial membrane-potential dye
TMRE. Treatment of trypanosomes with compounds 1a, 2, 4
and 5 resulted in a concentration-dependent decrease of
TMRE fluorescence relative to control parasites (Figure 4c),
reflecting drug-induced loss of mitochondrial membrane
potential. In contrast, no changes in fluorescence were
observed for compounds 3 and 7 (Figure 4c).
Figure 3. a) Schematic representation of PI-PLC assay. Incubation of unilamellar liposomes composed of egg PC and egg PA (3:1, molar ratio;
green symbols) and trace amounts of [3H]PI (red symbols) with PI-PLC results in hydrolysis of [3H]PI (to inositol cyclic phosphate and
diacylglycerol (DAG)) in the outer leaflet of the bilayer while [3H]PI in the inner leaflet is protected from the enzyme. As [3H]PI distributes equally
between the two leaflets during preparation of liposomes, approximately 50% is expected to be hydrolyzed by PI-PLC. In unilamellar liposomes
reconstituted with peptides, [3H]PI from the inner leaflet is translocated to the outer leaflet, where it becomes accessible to PI-PLC. b) Scrambling
activity of peptides 1a, 2, 3, 4 and 7 are shown in a dose response with a peptide phospholipid ratio between 0.001 to 0.1. c) Schematic
representation of the trapped NBD-glucose assay. Unilamellar liposomes trapped with NBD-glucose (orange star) are treated with peptides. If
a leakage occurs upon peptide addition, the NBD labelled glucose will be quenched by dithionite (purple symbol) and the decrease of the
fluorescence signal is measured. d) NBD-glucose leakage by the addition of peptide 1a, 2, 3, 4 and 7 at a phospholipid peptide ratio (PPR) of 0.1.
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Furthermore, examination of drug-treated trypanosomes
by transmission electron microscopy revealed changes in
mitochondrial ultrastructure, with the mitochondrial matrix
appearing less electron dense, while other intracellular
structures seemed unaffected (Figure 5). No changes were
seen when drug-treated parasites were examined by scanning
electron microscopy (Figure S4). Together, these results
demonstrate that compounds 1a, 2, 4, and 5 act on T. b.
brucei bloodstream forms by affecting mitochondrial ultra-
structure and causing loss of mitochondrial membrane
potential.
In Vitro Selection for Drug Resistance
To learn more about the mechanisms of trypanocidal drug
action, we attempted to select for drug-resistant mutants.
Bloodstream-form T. b. brucei of the “New York single-
marker” strain (NYsm)[26] were exposed to sublethal concen-
trations (0.5 nM–1.5 nM) of 2 in vitro. The cultures were
maintained and eventually sub-passaged in drug-containing
medium. However, there was no indication of developing
drug resistance. Parasite cultures always died off within
a couple of days when exposed to 1.5 nM 2, even after 7
months of selection. This may indicate that 2 disrupts
a fundamental process, which cannot readily be overcome
by a mutation in a single gene.
Having failed to obtain drug-resistant trypanosomes by
forward selection, we applied a reverse genetic approach to
select for resistance. For this purpose, an RNAi library
transfected into T. b. brucei NYsm was used,[27] which
consisted of about 12’000 pooled transfectants, each express-
ing a different small interfering RNA (siRNA) under the
control of a tetracycline promoter. This approach is powerful
for selecting loss-of-function mutants that exhibit drug
resistance when the expression of a particular gene is down-
regulated.[27] However, no resistant cells were obtained upon
induction of siRNA expression by addition of 1 mgmL@1
Figure 4. Qualitative and quantitative immunofluorescence staining of
NYsm parasites. a) Untreated NYsm parasites were stained with 4’,6-
diamidino-2-phenylindole (DAPI), MitoTracker and anti-ATOM40.
b) NYsm parasites were treated with 2 for one day and stained with
DAPI, MitoTracker and anti-ATOM40. c) The quantitative measurement
of the mitochondrial membrane potential with compounds 1a, 2, 3, 4,
5 and 7. The positive control carbonyl cyanide m-chlorophenyl hydra-
zone (CCCP) is also shown. DIC=differential interference contrast.
Figure 5. TEM Transmission electron micrographs of T. b. brucei
bloodstream forms. A shows a higher magnification view of the
cytoplasm of a non-treated control, the insert is the corresponding
lower magnification view. Nucleus (nuc) and parts of the mitochond-
rion with an electron dense matrix are discernible. Bar in A=0.25 mm;
insert=1.2 mm. B and C represent parasites treated with 5 nM 4 for
2 h. The mitochondrion (mito) retained an electron dense matrix, but
in many cases, parasites exhibited different degrees of vacuolization
(vac). Bar in B=0.35 mm, C=0.8 mm. In D, E and F parasites were
treated with 40 nM 4 for 2 h. D is a low magnification overview, the
boxed areas are magnified in E and F. The visible parts of the
mitochondrion have lost their characteristic electron dense matrix
(black arrows in E, F), and appear rounded and enlarged (F). The
ultrastructure of the flagellum (f) remains unaltered. Bars in
D=1.2 mm; E=0.45 mm; F=0.3 mm.
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tetracycline followed by selection
with 2 at 8.6, 17.1, or 25.7 nM.
Eflornithine was used as a positive
control for drug selection and re-
sulted in the identification of the





try[28, 29] was performed with the
two lead compounds 2 and 4 to
monitor their trypanocidal action
in real time (Figure S5). The two
compounds were studied at one- to
thirty-fold their EC50 (1 to 30 nM
for 2 ; 0.5 to 15 nM for 4).
Dose-dependent growth inhib-
ition was observed for both mole-
cules, that is, for 2 at 3 nM and for 4
at 1.5 nM, and substantially re-
duced growth of bloodstream-form
T. b. rhodesiense, but failed to kill
all parasites.
At 5 nM 4 or 10 nM 2, the
parasites were quickly killed within
24 hours (Table 2). Time to kill was
also dose-dependent. Onset of drug action was very fast for
both leucinostatin derivatives (Table 2).
Activity on further Protozoan Parasites
Encouraged by the high degree of activity of leucinostatin
A and its derivatives against T. brucei, we tested the lead
compounds 2 and 4 and tool compounds 3, 5 and 7 also against
the protozoan parasites Trypanosoma cruzi (causative agent
of Chagas disease), Leishmania donovani (visceral leishma-
niasis), Plasmodium falciparum (malaria tropica) (Table 3).
The IC50 values were in the nM range, except for 3 and 7
(Table 3), closely matching the results obtained in the T.
brucei assay.
Low nM IC50 values were seen against the axenically
grown amastigotes of L. donovani. The IC50 values of 2 and 4
on intracellular L. donovani were 18 nM and 50 nM, respec-
tively, indicating that the compounds have excellent cell
penetrating properties. This was confirmed in intracellular T.
cruzi parasites. Intra-erythrocytic P. falciparum were also
inhibited by 2 and 4 at 4.8 nM and 5.4 nM, respectively.
Conclusion
Developing peptides as drug candidates poses several
extra challenges as compared to small molecules, which has
limited their widespread use. One aspect is the inherent
biological instability of xenobiotic peptides and their rapid
enzymatic degradation in the body, limiting exposure. Never-
theless, peptide therapeutics continue to be in the focus of
current drug discovery and development projects due to their
distinct biological activities in academia as well as industry
and show increasing success rates.[30]
Previous reports showed that leucinostatin Awas toxic by
both oral and ip administration.[12,31] Synthetic modifications
of the natural product leucinostatin A by removal of the
Michael acceptor and replacement of the AHMOD amino
acid with either n-octyl or ethyl cyclohexyl moiety resulted in
equipotent derivatives. Compounds 2 and 4 inhibited growth
Table 2: Isothermal calorimetry measurements with a dose response
measurement of 2 and 4. With an increasing inhibitor concentration, the








drug free 38.3:0.8 108:1
2
1.0 2.2:0.7 39.9:0.8 115:5
3.0 3.3:2.6 35.3:4.2 101:15
10 <2 12.8:1.1 27:2.6
30 <2 15.2:1.5 31:3.3
4
0.5 5.5:6 40.0:2.5 112:6
1.5 4.2:2.1 33.5:3.2 97:13
5.0 <2 10.8:1.3 23:0.9
15 <2 13.7:2.3 28:3.5
Table 3: Activities of leucinostatin A (1a), 2–5 and 7 on different parasitic strains including the positive






























































chloroquine ND ND ND
4.9[d]
(3.8–6.2)
ND=not determined; [a] n=1; [b] n=2; [c] n=3; [d] n=4; [e] n=6; [f ] n=8.
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of protozoan parasites in the low nanomolar range, and
disrupted artificial liposomes in the same concentration
range, without dissolving, disintegrating or lysing them. The
active compounds allowed phospholipids to scramble from
one half of the bilayer to the other. Interestingly, T. brucei
parasites remained structurally intact, but lost the function-
ality of certain membrane systems, most notably the inner
mitochondrial membrane.
The leucinostatin derivatives exhibited the same SAR
against trypanosomes and liposomes. We determined the a-
helical nature of the compound, the protonation of the
terminal amine, and the hydrophobicity of the side chain to be
essential in both test systems, indicating the same mode of
action in each. The fast onset of the drug action as measured
by isothermal microcalorimetry supports this conclusion.
Destabilization of the inner mitochondrial membrane
represents a mode of action that incapacitates cells at a very
fundamental level and to which they cannot readily develop
resistance. This was shown by exposing T. brucei parasites to
sublethal doses of 2 for seven months, as well as by screening
against 12’000 siRNA knock-down mutants—none of which
developed resistance.
In comparison to the clinical approved drugs melarsoprol,
pentamidine and suramin, compounds 2 (ZHAWOC6025)
and 4 (ZHAWOC6027) are superior in their ability to kill T.
brucei parasites and, perhaps more importantly, showed no
signs of developing drug resistance. The inhibitors 2 and 4
represent a novel compound class for the treatment of T.
brucei infections and should be considered for application
against other parasitic diseases as well.
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